Bortezomib and Celecoxib for Advanced Solid Tumors
Author Information
Author(s): Hayslip John, Chaudhary Uzair, Green Mark, Meyer Mario, Dunder Steven, Sherman Carol, Salzer Shanta, Kraft Andrew, Montero Alberto J
Primary Institution: Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA
Hypothesis
The combination of the COX-2 inhibitor celecoxib and the ubiquitin-proteasome pathway inhibitor bortezomib is a potentially active clinical combination in the treatment of advanced solid tumors.
Conclusion
The combination of bortezomib and celecoxib was well tolerated, without dose limiting toxicities observed throughout the dosing ranges tested.
Supporting Evidence
- No dose-limiting toxicity was observed during the study period.
- Two patients had stable disease lasting for four and five months each.
- Sixteen patients developed progressive disease.
Takeaway
Doctors tested two medicines together to see if they could help people with serious tumors, and they found that the combination was safe to use.
Methodology
Patients received escalating doses of bortezomib and celecoxib in a phase I trial to determine the maximum tolerated dose and toxicity profile.
Limitations
The study was limited by the small sample size and the lack of a control group.
Participant Demographics
{"median_age":62,"sex_distribution":{"male":10,"female":8},"cancer_types":["Adrenocortical","Colon","Esophageal","Fallopian Tube","Hepatocellular","Leiomyosarcoma","Non-Small Cell Lung Carcinoma","Ovarian","Pancreatic","Renal Cell","Squamous Cell","Transitional Cell","Unknown Primary"]}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website